JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

JNJ

178.54

-0.28%↓

ABBV

207.55

-1.28%↓

UNH

305.14

-0.58%↓

AZN

79.7

-1.52%↓

NVS

125.09

-1.29%↓

Search

Eli Lilly and Co.

Closed

SectorHealthcare

696.49 -1.99

Overview

Share price change

24h

Current

Min

694.22

Max

712.89

Key metrics

By Trading Economics

Income

2.9B

5.7B

Sales

2.8B

16B

P/E

Sector Avg

45.864

35.473

EPS

6.31

Dividend yield

0.8

Profit margin

36.384

Employees

47,000

EBITDA

3.3B

7.5B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+31.86% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.80%

2.38%

Next Earnings

30 Oct 2025

Next Dividend date

10 Sept 2025

Next Ex Dividend date

14 Nov 2025

Market Stats

By TradingEconomics

Market Cap

-62B

629B

Previous open

698.48

Previous close

696.49

News Sentiment

By Acuity

39%

61%

128 / 372 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Eli Lilly and Co. Chart

Past performance is not a reliable indicator of future results.

Related News

7 Aug 2025, 11:36 UTC

Earnings

Eli Lilly Lifts Full-Year Outlook After Revenue Surges on Zepbound, Mounjaro Demand

12 Aug 2025, 22:15 UTC

Acquisitions, Mergers, Takeovers

Lilly CEO Buys $1 Million of Stock After Share-Price Drop on Obesity Drug Data -- Barrons.com

8 Aug 2025, 19:34 UTC

Market Talk

Underwhelming Weight Loss Pill Results Might Not Put Off Consumers -- Market Talk

8 Aug 2025, 05:32 UTC

Market Talk

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

7 Aug 2025, 16:20 UTC

Earnings

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 4th Update

7 Aug 2025, 14:18 UTC

Market Talk
Earnings

Eli Lilly's Orforglipron Results Weigh on Stock -- Market Talk

7 Aug 2025, 13:54 UTC

Earnings

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 3rd Update

7 Aug 2025, 12:12 UTC

Earnings

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- 2nd Update

7 Aug 2025, 11:58 UTC

Earnings

Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm -- Update

7 Aug 2025, 11:32 UTC

Earnings

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 Aug 2025, 11:03 UTC

Earnings

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

7 Aug 2025, 10:49 UTC

Earnings

Eli Lilly 2Q Gross Margin 84.3% >LLY

7 Aug 2025, 10:48 UTC

Earnings

Eli Lilly 2Q Volume Rose 42%, Realized Prices Fell 6% >LLY

7 Aug 2025, 10:47 UTC

Earnings

Eli Lilly Raises 2025 Adjusted Performance Margin View to 43%-44.5% From 41.5%-43.5% >LLY

7 Aug 2025, 10:46 UTC

Earnings

Eli Lilly Had Seen 2025 Adjusted EPS $20.78-$22.28 >LLY

7 Aug 2025, 10:46 UTC

Earnings

Eli Lilly Had Seen 2025 Revenue $58B-$61B >LLY

7 Aug 2025, 10:46 UTC

Earnings

Eli Lilly Raises 2025 View To Rev $60B-$62B >LLY

7 Aug 2025, 10:45 UTC

Earnings

Eli Lilly 2Q Net $5.66B >LLY

7 Aug 2025, 10:45 UTC

Earnings

Eli Lilly 2Q Rev $15.56B >LLY

7 Aug 2025, 10:45 UTC

Earnings

Eli Lilly Sees FY Adj EPS $21.75-Adj EPS $23.00 >LLY

7 Aug 2025, 10:41 UTC

Earnings

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

6 Aug 2025, 20:34 UTC

Earnings

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

6 Aug 2025, 08:45 UTC

Earnings

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

30 Jul 2025, 10:38 UTC

Market Talk

Novo Nordisk Could Struggle to Regain Investors' Trust -- Market Talk

29 Jul 2025, 17:05 UTC

Earnings

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- 3rd Update

29 Jul 2025, 16:55 UTC

Earnings

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

29 Jul 2025, 13:35 UTC

Earnings

Novo Nordisk Shares Plummet as Competition Weighs on Sales -- Update

29 Jul 2025, 11:39 UTC

Earnings

Novo Nordisk Stock Tumbles 20% After Ozempic Maker's Shock Cut to U.S. Outlook -- Barrons.com

25 Jul 2025, 12:49 UTC

Acquisitions, Mergers, Takeovers

Lilly Completes Acquisition Of Verve Therapeutics To Advance One-time Treatments For People With High Cardiovascular Risk >LLY VERV

24 Jul 2025, 12:02 UTC

Acquisitions, Mergers, Takeovers

Eli Lilly Expects to Complete Verve Acquisition on July 25 >LLY VERV

Peer Comparison

Price change

Eli Lilly and Co. Forecast

Price Target

By TipRanks

31.86% upside

12 Months Forecast

Average 938.39 USD  31.86%

High 1,190 USD

Low 700 USD

Based on 22 Wall Street analysts offering 12 month price targets forEli Lilly and Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

22 ratings

17

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

N/A / 884.54Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Strong Bearish Evidence

Sentiment

By Acuity

128 / 372 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.